These are top 10 stocks traded on the Robinhood UK platform in July
LONDON - Hikma Pharmaceuticals (OTC:HKMPY) PLC (LSE:HIK), a global pharmaceutical company, has revealed its medium-term financial guidance in conjunction with a site visit for analysts and investors at its US manufacturing and research facility in Columbus (WA:CLC), Ohio. The company projects a compound annual growth rate (CAGR) in Group revenue of 6% to 8% from 2024 to 2027, and a core operating profit growth of 7% to 9% over the same period.
During the visit, participants are gaining insights into Hikma’s operations at its 1,000,000 square foot Columbus facility, which is instrumental in producing a variety of generic and specialty products, including oral and respiratory medications. Hikma’s presence in the US is significant as one of the country’s largest suppliers of generic medicines. The event also includes a tour of the company’s recently acquired Injectables facility in Bedford, Ohio.
In a strategic move, Hikma announced the rebranding of its Generics business to Hikma Rx, emphasizing its commitment to offering complex and differentiated prescription medicines. This rebranding aligns with the company’s focus on long-term, sustainable growth within its segments.
Additionally, Hikma has set an ambitious revenue target, aiming to achieve $5 billion by the year 2030. This goal underscores the company’s confidence in its growth trajectory and strategic initiatives.
The presentation delivered during the site visit is accessible on Hikma’s website, and a recording, along with a transcript of the presentation and subsequent question and answer session, will be made available post-event. This announcement is based on a press release statement issued by Hikma Pharmaceuticals PLC.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.